In temperate regions of the world, seasonal influenza causes yearly epidemics that peak in the winter. It is an acute viral infection that spreads easily from person to person. As new medicines for the treatment and prevention of seasonal influenza are licensed in the upcoming years, it is anticipated that the dynamics of the seasonal influenza market will alter. Additionally, there are candidates in the pipeline for seasonal influenza in late-stage, middle-stage, and early-stage clinical development, which will increase the market size for seasonal influenza in the future. Furthermore, the recent pandemic has expedited improvements in the market for seasonal influenza. Additionally, the development of adaptable technologies will increase the demand for seasonal influenza vaccines.
The healthcare industry has undergone unheard-of transformations as a result of the COVID-19 epidemic. The sector is anticipated to reap the benefits of increased demand for seasonal influenza vaccines in the near future in order to boost protection against the dangerous pandemic. Improved R&D that creates a new COVID-19 vaccine is therefore anticipated to increase the market's potential for sales. The COVID-19 epidemic during the pandemic time significantly impacted market expansion. Patients must receive vaccinations for safety reasons because COVID-19 affects the respiratory system. As a result, the seasonal flu vaccine has become more common.
Strong R&D Investments and Candidates with a Strong Pipeline to Drive Market Growth
Leading market companies like CSL Limited, Sanofi, and GlaxoSmithKline plc are investing more in R&D to improve their manufacturing capacities and concentrate on releasing new vaccines, which is what is driving the industry's continued growth. CSL Limited revealed intentions to build a new biotech manufacturing facility in Australia in November 2020. This, together with the robust vaccination pipeline and rising government financing, has made it easier to introduce therapeutically effective vaccines. Additionally, pharmaceutical firms are concentrating on funding R&D to provide new possible vaccines.
Seasonal Influenza Vaccine Side Effects and a Lack of Qualified Professionals Will Both Constrain Market Expansion
Over the projection period, the growth of the worldwide seasonal influenza market may be restrained by a shortage of competent staff who cannot treat patients with the proper medications. Additionally, vaccines have a variety of adverse effects that undoubtedly slow market expansion. Side effects like fever, chills, endurance, discomfort and soreness, among many others, hamper the seasonal influenza market's expansion.
Based on type, the seasonal influenza market is segmented into influenza A viruses, influenza B viruses, influenza C virus, influenza D viruses and others. The influenza A viruses category dominated the market in 2022. The most common viral cause of adults' acute respiratory distress syndrome (ARDS) is the influenza A virus. Age between 36 and 55, pregnancy, and obesity are risk factors independently linked to ARDS, whereas female sex, influenza vaccination, and infections with influenza A are protective factors (H3N2).
Based on treatment, the seasonal influenza market is segmented into Antiviral, Neuraminidase Inhibitors, Vaccination, and Others. The antiviral category dominated the market in 2022. Antiviral medications are essential in managing and preventing influenza by treating the patient's infection and preventing serious illnesses brought on by the flu, such as bacterial pneumonia. These medications limit the discharge of viral particles from infected host cells by blocking neuraminidase activity on the virus surface.
By Route of Administration
Based on the route of administration, the seasonal influenza market is segmented into oral, parenteral and others. The oral category dominated the market in 2022. Oral medications are anticipated to accelerate market expansion. Given that most medications are accessible in capsule and tablet form and this is a very practical mode of administration, the category is anticipated to accelerate the global market.
Based on treatment, the seasonal influenza market is segmented into hospitals, homecare, specialty clinics, and others. The hospital's category dominated the market in 2022 due to the presence of skilled professionals.
By Distribution Channel
Based on treatment, the seasonal influenza market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy category dominated the market in 2022. The fact that vaccinations are typically preferred and carried out at smaller institutions accounts for this dominating position. In the coming years, a high market value is anticipated partly due to the hospitals' enormous supply of vaccines.
North America is projected to hold the largest share of the seasonal influenza market over the forecast period. The region's market is anticipated to increase due to the quick introduction of efficient products and technologically sophisticated vaccine manufacturing facilities. Additionally, the market's expansion in North America is anticipated to be fueled by the rising occurrence of seasonal influenza and the high sales of its medication. On the other hand, the Asia Pacific seasonal influenza market is anticipated to grow significantly over the forecast period. It is projected that market expansion will be driven throughout the area by the rising number of government initiatives to offer flu vaccines and raise awareness about seasonal influenza. Additionally, the region's expanding population in nations like China and India and the desire for efficient treatments driving up sales, are anticipated to fuel market expansion.
LIST OF KEY COMPANIES PROFILED:
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Sanofi (France)
- Boehringer Ingelheim International GmbH (Germany)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- SHIONOGI & Co., Ltd (Japan)
- SINOVAC (China)
- March 2022: Fluzone is a high-dose influenza vaccination introduced by Sanofi. The flu shot gives defense against four different types that are present in Australia.
- September 2021: To assess the efficacy, immunogenicity, and safety of a single-dose quadrivalent mRNA vaccine against influenza in healthy individuals, Pfizer Inc. started phase 1 clinical research.
|Unit||Revenue (USD Million) and Volume (Kilo Tons)|
|Segmentation||By Type, By Treatment, By Route of Administration, By End-User, By Distribution Channel and By Geography|
|By Route of Administration||
|By Distribution Channel||